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ABSTRACT 
Aim: To describe the profile of patients with gestational diabetes mellitus (GDM) at 
Tygerberg Academic Hospital, managed according to the new Provincial Guidelines.  
Methods: There was the performance of a retrospective audit of all pregnant patients with 
GDM, seen at the Special Care Clinic of Tygerberg Academic Hospital over a period of 12 
months. Dictation of the size of the study sample was by the time interval and the number 
of patients diagnosed with GDM and seen at the clinic during the period of study. Patient 
data were extracted from the files and loaded into a spreadsheet in a strictly anonymous 
fashion. Within the patient profile the study sought to identify the mode of diagnosis, 
interventions required, as well as the courses of the pregnancies for both the women and 
their foetuses. There was the use of descriptive statistics for analysis, and logistic regression 
was employed to investigate continuous variables (age and body mass index).   
Results: One hundred and forty-seven women had the diagnosis of GDM from August 2010 
to July 2011. Fifty-eight percent of women had a positive family history of diabetes; 57% 
developed glycosuria, and 38% underwent diagnostic testing due to morbid obesity. 
Previous GDM and previous unexplained IUD were present in 8% of women. The median age 
of the women in this group was 32 years and 80% were found to be obese. The median 
gestational age at diagnosis was 28 weeks with a median glycosylated haemoglobin of 6.3%. 
The upper range of glycosylated haemoglobin (13.3%) and the lower range of gestational 
age at diagnosis (7 weeks) indicate that cases of undiagnosed, pre-existing diabetes mellitus 
were also present in this group of women with “gestational diabetes”.  Concerning glycemic 
control during pregnancy 23% responded to lifestyle modification alone, 68% required 
additional metformin and 9% insulin as a final addition to therapy. It is noteworthy that 
despite the diagnosis of GDM, 29% of women still required metformin at discharge. Twenty-
nine percent of the group delivered before 38 weeks’ gestation with hypertensive 
complications (14%) and spontaneous pre-term labour (8%) featuring prominently. The 
median birth weight was 3280 grams. There was a high incidence of peripartum foetal 
distress (26%) reflected in the caesarean rate of 55%.  
Stellenbosch University  https://scholar.sun.ac.za
4 
 
 Conclusion: A positive family history, obesity and glycosuria are useful to diagnose GDM. 
Although approximately one-quarter of women achieved glycemic control on lifestyle 
modification alone; most required metformin but avoided insulin therapy. Despite the goal 
of elective delivery at 38 weeks’ gestation, hypertensive complications and spontaneous 
pre-term labour resulted in many earlier deliveries. The overall rate of caesarean section 
was high but during vaginal delivery shoulder dystocia was rare. The policy of screening 
using history and selective clinical findings, together with the addition of metformin to the 
management programme (as advocated by the provincial guidelines) appears to be fulfilling 
its purpose within the specific context of public health care within the Western Cape 
Province of South Africa. 
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Chapter 1 
Introduction and context 
Gestational diabetes mellitus (GDM) is a common and important medical condition of 
pregnancy. The incidence of GDM has been found to be as high as 8.8% in some regions of 
South Africa [1]. This incidence of GDM is likely to increase as the South African society 
becomes more obese [2].  Diabetes in pregnancy has an association with an increased 
perinatal mortality rate [3].  Gestational diabetes mellitus has an association with some 
adverse outcomes, which include: foetal macrosomia, birth trauma, primary caesarean 
delivery, neonatal hypoglycaemia, shoulder dystocia and preeclampsia [4, 5].  
Recent robust studies have shown benefit in treating women with milder forms of GDM.  
Examples of these benefits are a reduction in the incidence of macrosomia, reduction in 
maternal weight gain and preeclampsia in experimental groups compared to controls [6,7,8]. 
Despite these benefits, no reduction in perinatal death rates has been demonstrated for the 
specific sub-group with milder forms of GDM (cases falling below previously accepted cut-
off values) [6]. However to expand the benefits of decreased perinatal morbidity more 
women need to be treated. 
Lifestyle modification (diet and exercise) is a long-standing pillar of diabetic management.  
The oral biguanide agent, metformin is a recent, non-invasive, safe addition to standard 
practice. Recent studies comparing the benefits and risks of oral agents to insulin for the 
management of GDM have shown no substantial differences in major outcomes [9, 10]. 
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Chapter 2 
Literature review 
Gestational diabetes mellitus (GDM) by definition is any degree of glucose intolerance 
diagnosed for the first time in pregnancy [11, 12, 13]. This definition does not exclude glucose 
intolerance that may have been present before the pregnancy and whether the intolerance 
normalises after the pregnancy [13]. Prevalence of GDM is on the rise with many implications 
for maternal health, pregnancy outcomes and foetal health. It is of importance to identify 
and diagnose those women at high risk of GDM, monitor their pregnancies closely and treat 
the glucose levels to try and minimise adverse pregnancy outcomes. Also of importance is to 
flag them out for the possible long-term development of DM later in their life or for possible 
recurrence of GDM in subsequent pregnancies. 
2.1. Prevalence of gestational diabetes mellitus 
In one South African study, the prevalence of GDM was found to be 8.8% among rural 
pregnant women in Limpopo province [1]. In a Canadian study by Liu and colleagues they 
found the prevalence of GDM to be higher in First Nations women when compared with 
Non-First Nations women in Ontario (6.5 vs. 4.2%, P < 0.001), with the overall prevalence of 
diabetes 10.3 vs. 6.0%, P < 0.001, respectively. The mean age of women with GDM was 
younger for First Nations women (28.76 ± 6.98 vs. 32.79 ± 5.39 years, P < 0.001) [14]. The 
incidence of GDM is rising globally due to some factors that include the rising prevalence of 
obesity and pregnancy complications relating to it. Previously problematic in developed 
countries, it is now an epidemic in the developing countries as well. In the USA by 2002 one-
third of adult women were found to be obese (NHANES) and African-Americans were the 
most affected (49%) [2]. In Canada there was a 13% rise in obesity among adult women from 
1992 (40%) to 2004 (53%) when compared with a 6% rise from 1978 (34%) to 1992 (40%) 
and in South Africa 38% of adults (age>15years) were obese by 1998 [2]. The incidence of 
gestational diabetes is said to have increased from 10 to 100 percent in some race/ethnicity 
groups in the past 20 years and its frequency usually reflects the frequency of type 2 
diabetes in the underlying populations [15, 16, 17].  
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2.2. Screening for and diagnosis of gestational diabetes mellitus 
The purpose of screening for any medical condition is to distinguish people who probably 
have a condition from those who probably do not. This screening is followed by a diagnostic 
test for those who have screened positive. The health-care system offers screening, and it is 
important that it causes no harm. Screening programmes need to meet certain criteria as 
set by the World Health Organisation (WHO) before initiation of screening is. Screening for 
GDM has therefore been very controversial because it meets some of these criteria, but not 
all of them [18]. 
The most important criteria are: 
 The condition should be an important health problem. 
 All the cost-effective primary prevention interventions should have been 
implemented as far as practicable. 
 There should be a simple, safe, precise and validated screening test. 
 The distribution of test values in the target population should be known, and a 
suitable cut-off level defined and agreed. 
 There should be an agreed policy on the further diagnostic investigation of 
individuals with a positive test result and on the choices available to those 
individuals. 
 There should be an effective treatment or intervention for the patients identified 
through early detection, with evidence of early treatment leading to better 
outcomes than late treatment. 
 There should be agreed evidence-based policies covering which individuals to offer 
treatment and the appropriate treatment to be offered. 
 There should be evidence from randomised controlled trials that the screening 
programme is effective in reducing mortality and morbidity. 
 The benefit from screening should outweigh the physical and psychological harm 
(caused by the test, diagnostic procedures and treatment). 
 The opportunity cost of a screening programme (including testing, diagnosis and 
treatment, administration, training and quality assurance) should be economically 
balanced about expenditure on medical care as a whole [18]. 
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Controversy surrounding screening for gestational diabetes stems from the fact that there is 
no consensus on universal screening methods or agreed policies. There are also differences 
in population features of pregnant women globally and lack of evidence based on 
randomised controlled trials on screening versus no screening of patients. Tere is also a lack 
of precise and cost-effective screening tests, and differences in health care resources in 
different countries or regions of the world. 
Despite the aforementioned, there is agreement on the fact that GDM is a significant health 
problem (the diagnosis is associated with adverse pregnancy outcomes and the risk of 
future diabetes in the mother) [18, 19, 20]. It has also been proven that elevated glucose levels 
less than diabetic levels and unknown to the woman and her carers can also have adverse 
pregnancy outcomes (such as large for gestational age (LGA) or macrosomic babies, 
neonatal hyperinsulinism at birth, neonatal hypoglycaemia, increased adiposity, shoulder 
dystocia and birth injury, neonatal hyperbilirubinaemia, primary caesarean section and pre-
eclampsia). These outcomes were demonstrated in the Hyperglycaemia and Adverse 
Pregnancy Outcomes (HAPO) study. However, the study did not show that hyperglycaemia 
less than that of overt diabetes has an increase in perinatal mortality [19, 21].  
Early detection of diabetes is important, and screening detects diabetes at an asymptomatic 
stage. Treatment of hyperglycaemia in pregnancy is effective, and treatment of GDM has 
been shown to be effective in reducing adverse events [18, 22]. Screening refers not only to 
plasma or capillary glucose testing but also to identifying risk factors. So in selective 
screening, the first step involves identifying risk factors such as age and BMI. The selective 
screening would occur at the booking clinic (or ideally, before conception) with a view to 
preventing hyperglycaemia in pregnancy. Only those women with risk factors would 
proceed to the second step using blood glucose tests [18]. Pregnant women who fulfil the 
criteria for low-risk pregnancy need not undergo screening for GDM. Women with risk 
factors such as marked obesity, a history of prior GDM, glycosuria or a strong family history 
of diabetes and previous adverse pregnancy outcomes should undergo glucose testing. If 
they do not have GDM on the initial screening (negative screening results), they should be 
retested between 24 and 28 weeks of gestation [20].  Traditionally screening for GDM has 
been done at 24 – 28 weeks of pregnancy, but some commentators have raised concern 
about leaving it so late. In the American College of Obstetricians and Gynaecologists (ACOG) 
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2001 guidelines, it states that insulin resistance increases with pregnancy progression and 
testing later in pregnancy will have a higher yield of abnormal tests. The later the 
abnormality is diagnosed; the less time will be available for intervention [11]. 
Screening will not only help in detecting hyperglycaemia but also early detection of 
undiagnosed type 2 diabetes. The severity of complications associated with this condition, 
which include congenital abnormalities and increased perinatal mortality justifies such 
screening [18]. The issue is about screening and treating at glucose thresholds higher than 
normal, but lower than diabetic levels. Two studies addressed this issue, namely the 
Australian Carbohydrate Intolerance Study (ACHOIS) and the Maternal-Foetal Medicine 
Units Network treatment of mild gestational diabetes (MFMUN-GDM). These studies 
demonstrated that diagnosis and treatment of GDM are worthwhile, as this does reduce the 
risk of many adverse pregnancy outcomes of GDM without causing harm [7, 8]. There is broad 
agreement about treating women with the highest glucose levels, but uncertainty as 
illustrated by disagreement amongst guidelines and policies, about management of lesser 
degrees of hyperglycaemia [18]. The ACHOIS and NICHD-MFMU Network trials have shown 
that intervention at lower levels specified in these trials is worthwhile and cost effective [4,7]. 
However, there are no randomised clinical trials on screening versus no screening [22]. 
The harms of screening include the inconvenience of screening and diagnostic follow-up and 
the anxiety raised by screening tests. The harms may come partly from the impact of the 
diagnosis rather than the condition, such as the increased rate of caesarian sections [18]. The 
harms of interventions also need to be considered, including insulin treatment and 
hypoglycaemia [23]. According to Kjos and Buchanan only 20 – 30% of babies of women with 
GDM have macrosomia [24]. A Cochrane review found that reducing macrosomia did not 
necessarily reduce the rates of Caesarean section, forceps delivery or birth trauma [25]. The 
balance of harms and benefits will depend partly on the prevalence of hyperglycaemia in 
pregnancy. This is because the number of women who need to be screened to detect one 
case of hyperglycaemia in pregnancy will fall as the prevalence rises [18]. 
There is a range of options that have been proposed to screen for GDM. Screening tests do 
not refer only to blood glucose. Clinical risk factors are easy to record and are identifiable at 
the booking visit. Identification of the clinical risk factors would be the basis for selection 
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and only those considered to be high-risk would go on to have their blood glucose 
measured. Blood glucose levels can be taken at varying times e.g. fasting, random, and post-
prandial following an oral or intravenous glucose load or following a standardised meal [18]. 
The International Association of Diabetes and Pregnancy Study Groups (AIDPSG) consensus 
panel advocated testing all women with a 75g oral glucose tolerance test (OGTT) at 24 – 28 
weeks. Earlier testing only for the women who had been found to have abnormal glucose 
levels earlier in pregnancy or were known to have diabetes [26]. The UK National Institute for 
Health and Clinical Excellence (NICE) recommended selective screening based on the 
American Diabetes Association (ADA) criteria, or on high-risk ethnicity [27]. The basis of this 
recommendation was on the probability of being diagnosed with GDM on the basis of a 75g 
OGTT, and so belongs to the dichotomy era [18]. A health technology assessment (HTA) 
report published in 2002 concluded that selective screening by risk factors would miss about 
half of the women with GDM [28]. A before and after study from Paris, comparing selective 
versus universal screening reported that GDM was diagnosed in 8.3% and 12.6% 
respectively [29].    
Summary of some international screening programmes 
 American Diabetes Association (ADA): Risk assessment for GDM should be at the first 
prenatal visit. Women at high risk of GDM should undergo an OGTT as soon as 
feasible. If not found to have GDM at initial screening, they should be retested 
between 24 and 28 weeks of gestation. Women of average risk should have testing 
at 24 – 28 weeks. Low-risk status requires no testing. Initial screening using 50g 1-hr 
oral glucose challenge test (GCT) should precede an OGTT on women exceeding the 
threshold value on the GCT [30].  
 Canadian Diabetes Association (CDA): all pregnant women should undergo screening 
for GDM between 24 and 28 weeks gestation. Women with multiple risk factors 
should undergo screening in the first trimester [31]. 
 International Association of Diabetes and Pregnancy Study Groups (IADPSG): first 
phase: first prenatal visit, detection of women with overt diabetes or GDM using 
fasting plasma glucose, HbA1c or random glucose on all, or only high-risk women. 
Decision-based on background frequency of abnormal glucose metabolism in the 
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population or on local circumstances. Second phase: 75g OGTT at 24 – 28 weeks in 
all women not previously found to have overt diabetes or GDM [26]. 
 National Institute for Health and Clinical Excellence (NICE): women offered screening 
at booking appointment using any of five risk factors for GDM. Early self-monitoring 
of blood glucose or a 2-hr 75g OGTT at 16 – 18 weeks to test for GDM if the woman 
has had GDM previously followed by an OGTT at 28 weeks if the first test is normal. 
An OGTT should be done to test for GDM at 24 – 28 weeks if the woman has any 
other risk factor. The NICE guidelines excluded age, because; advanced maternal age 
should not be used as a risk factor because this would result in pregnant women 
requiring an OGTT (section 33) [27].  
The OGTT has been the standard test for diagnosing GDM, often preceded by a screening 
test such as clinical risk factors or a 50g GCT. Various OGTTs with different glucose loads 
(50g, 75g and 100g glucose) and different durations (2-h and 3-h) have been used [18]. The 
HAPO study has led to the IADPSG consensus recommending standardisation on a glucose 
load of 75g and glucose testing at fasting, 1-h and 2-h [26]. The OGTT has however been 
found by Agarwal and Dhatt to have some shortcomings of being expensive and time 
consuming. It is non-physiologic, unpleasant, not reproducible, unrelated to body weight, 
and its predictive value may vary with ethnic origins [32].  
As an alternative to an OGTT, the fasting plasma glucose (FPG) as a screening test is easy to 
administer, well tolerated, inexpensive, reliable and reproducible [32, 33, 34]. They note that 
the value of FPG varies according to the diagnostic criteria used: good with the ADA criteria 
and poor with the WHO criteria [34]. One problem with FPG is that it misses post-prandial 
hyperglycaemia, which may be enough to cause overgrowth of some foetuses [23, 35]. 
Measurement of HbA1c is a current recommendation by an expert committee for 
diagnosing non-gestational type 2 diabetes because advances in its measurement have 
made it a more reliable and standardised, test [36].  Measurement of HbA1c at the same time 
as 75g OGTTs at 24 – 28 weeks in a high-risk population yielded overlapping results in 
women with and without GDM. Therefore, no level of HbA1c could be used as a cut-off to 
rule out GDM. Other studies reviewed by Agarwal and colleagues nearly all reported that 
HbA1c was not useful [37].  Aldasoqui and Gossain suggested that using the serial 
measurement of HbA1c at four weekly intervals starting around mid-pregnancy might 
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reduce the numbers of women requiring OGTT [38]. The HAPO study measured HbA1c at the 
time of the OGTT and found a rise with advancing gestational age [39]. 
Simplified OGTTs have been suggested as an alternative to a full OGTT, and they could make 
screening much more convenient. Anderberg, et al., used a 75g load but measuring only the 
2-h plasma glucose, (with the cut-off at 9mmol/l for diagnosing GDM) and those in the 
borderline group of 7.8 – 8.9mmol/l getting a repeat OGTT a week later [40]. Anjalakshi, et 
al., compared a 75g GCT (non-fasting) with the standard OGTT. They found no difference in 
their population, implying that it makes no difference whether the women have fasted or 
not [41]. Ayach, et al., used a 100g OGTT shortened by using a 1-h level of under 7.8mmol/l to 
rule out GDM and no measurement at 2-h and 3-h [42]. 
Although screening for HGP does not meet all criteria usually required for implementation 
of screening programmes, its case has been strengthened in recent years by: 
 The rising prevalence due to rising incidence of obesity and women having babies 
later in life. 
 The demonstration by the HAPO study that adverse outcomes occur across a wider 
range of plasma glucose than previously thought to be the case. 
 The results of the ACHOIS and NICHD-MFMUN trials showing that treatment at lower 
levels of PG is effective. 
 The knowledge that metformin and glibenclamide are safe and effective, making 
treatment easier and cheaper.   
Given advances in the evidence base from these and other studies, it is unlikely that there 
will be a randomised trial of screening versus no screening. Therefore, the uncertainties 
around the remaining unmet criteria might have to be met by a further analysis of existing 
data from large studies such as HAPO [18]. 
2.3. Management of gestational diabetes mellitus 
The aim of the management of GDM is to achieve tight glycemic control to prevent adverse 
pregnancy outcomes. Management entails lifestyle modification (diet and exercise), oral 
glycemic agents (metformin and glibenclamide) and insulin or a combination of these 
methods as required. The 5th International Workshop-Conference on GDM made 
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recommendations relating to glycaemia in GDM pregnancies, and the potential role of foetal 
growth targets. The recommendation was to maintain capillary blood glucose at < 5.3 
mmol/L (fasting state), < 7.8 mmol/L at 1- h and < 6.7 mmol/L at 2-h after starting a meal 
[51]. Careful analysis of the metformin versus insulin in gestational diabetes study (MiG 
study) showed a strong association between the level of glycaemia achieved and pregnancy 
outcomes. The authors of the MiG study commented that lower glycemic targets might be 
necessary [9]. 
Lifestyle modification is an important component of the management of GDM, and it entails 
proper diet to ensure appropriate weight gain in pregnancy and exercise to burn calories as 
well as limit excess weight gain. Pregnant women with GDM should be evaluated and 
followed up by a registered dietician to ensure that nutrition promotes euglycaemia, 
appropriate weight gain and adequate nutritional intake [43, 44, 45, 46].  Exercise or physical 
activity should be encouraged unless there are specific obstetric contraindications or if the 
glycemic control is worsened by the activity [47, 48]. To delay efforts at improvement of 
lifestyle changes until after diagnosis of GDM at 24 – 32 weeks of pregnancy is almost 
certainly a lost opportunity. Efforts to improve the lifestyle of women at risk of GDM, both 
pre-pregnancy and from early pregnancy need to be considered. Such an approach has a 
potential of preventing GDM as well as improving short and long-term outcomes for 
mothers and babies [19]. Frequent monitoring using self-monitoring of blood glucose is 
essential to guide treatment, and both fasting and postprandial testing are recommended to 
guide therapy to reach glycemic targets [49, 50].  
Patients who fail to control their glucose after lifestyle modification need to be put on 
pharmacological treatment while being encouraged to continue with lifestyle modification 
as part of the treatment. Rowan, et al., in 2008 studied women with GDM, who were 
randomly assigned to open treatment with metformin (with supplemental insulin if 
required) or insulin. Of the women assigned to metformin, 43.6% required supplemental 
insulin. Metformin (alone or with supplemental insulin) was not associated with increased 
perinatal complications when compared with insulin only. There was less severe 
hypoglycaemia in neonates whose mothers received metformin, but more spontaneous 
preterm deliveries (i.e. < 37weeks gestation) occurred in this group [51, 52]. Other studies 
have confirmed the safety of metformin, demonstrating less neonatal hypoglycaemia [53]. 
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One study conducted to compare metformin with glyburide, however, did not corroborate 
the findings of increased prematurity in the metformin group [54]. While metformin appears 
to be a safe alternative to insulin therapy, it does cross the placenta, plus metformin 
clearance increases in pregnancy [55]. Results of the follow-up of children from the 
Metformin in Gestational diabetes trial (Mig-TOFU), expected in several years, will provide 
more data on the safety of metformin in pregnancy [56]. Metformin appears safe and 
effective in the treatment of GDM, and it reduces the requirement for supplementary 
insulin. Women treated with metformin have a significantly lower incidence of macrosomia 
and large for gestational age (LGA) neonates as well as a reduced rate of caesarian section 
[57].  
Insulin is an effective therapy for maternal glucose control. However it is expensive, must be 
injected and requires skilled handling [54]. The use of insulin to achieve glycemic targets has 
been shown to reduce foetal and maternal morbidity [58, 59]. There has been use of a variety 
of protocols with multiple injections being the most effective [60]. Insulin usually needs to be 
continuously adjusted to achieve glycemic targets [56]. Women with obesity, high fasting 
blood glucose and early need for pharmacological treatment may be more suitable for 
insulin therapy [61].  
2.4. Complications of gestational diabetes mellitus  
GDM has many implications for both the baby and the mother. These implications are short 
term, and long term, and prevention or treatment of GDM can help in decreasing their 
incidence.  
Short-term complications of hyperglycaemia in the foetus include LGA/macrosomic babies, 
neonatal hyperinsulinism at birth (as reflected by elevated cord C-peptide), neonatal 
hypoglycaemia, excess neonatal adiposity, shoulder dystocia or birth injury, neonatal 
hyperbilirubinaemia, bone fractures, nerve palsies and death. With the increasing 
prevalence of diabetes, some women may be diagnosed with GDM when in fact they have 
unknown pre-existing diabetes in particular type 2 diabetes mellitus (T2D). The outcomes of 
T2D may be comparable to those of type 1 diabetes mellitus (T1D). These adverse outcomes 
include increased rates of congenital malformation and perinatal death [62, 63].  
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There may be a question whether there is long-term evidence showing that the intrauterine 
environment of GDM can contribute to adult disease? There is evidence in animal studies 
but human data is more limited [64]. There was an association between maternal diabetes in-
utero and age at offspring’s diagnosis of T2D in the multi-ethnic SEARCH for diabetes in 
youth study [65]. Both lines of evidence support the concept that exposure to 
hyperglycaemia in-utero increases the subsequent risk of diabetes in the offspring. The mild 
hyperglycaemia of GDM, however, was not considered in these studies [19]. In a Danish 
study, offspring of women with diet-controlled GDM and women with T1D were followed 
up, and a prevalence of 21% of T2D/pre-diabetes at 22years was present. Offspring of 
women with GDM are at a significantly higher risk of overweight (obesity) and T2D. While it 
is difficult to determine the relative contributions of the intra-uterine environment 
compared with genes and the post-pregnancy environment on these findings in the children 
of GDM women, the same trends for the children of T1D women strongly indicate that the 
hyperglycaemia of the intra-uterine environment is important. This conclusion is reinforced 
by the finding of an association between maternal glucose control late in pregnancy and the 
risk of T2D/pre-diabetes in the offspring of the T1D mothers [66, 67].  
Women with GDM are very often on a pathway to the development of T2D. In an Australian 
study of 5470 GDM patients and 783 control subjects, the risk of developing diabetes was 
9.6 times greater for patients with GDM. The cumulative risk of T2D for the GDM patients 
was 25.8% at 15 years post diagnosis [68]. In a systematic review of 28 studies, the 
cumulative incidence of T2D following GDM ranged from 2.6% to 70%. There were 
considerable differences across the studies in factors such as duration of follow-up (6 weeks 
to 28 years), diagnostic criteria used for GDM used and the rate of retention of subjects in 
follow-up [69]. GDM is also a risk factor for cardiovascular disease (CVD) events. In a large 
population-based study in Canada, women who had GDM when compared with a matching 
control group were at a slightly higher risk of CVD events with a hazard ratio of 1.71 (95% CI; 
1.08 – 2.69). After adjustment for the development of T2D, this hazard ratio was no longer 
significant such that a considerable part of post-GDM increased  CVD risk was attributable to 
progression to T2D [70]. 
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2.5. Motivation for the study  
The Western Cape Provincial Guideline for Management of Diabetes in Pregnancy 
(WCPGMDP) has recently recommended the addition of oral medication, metformin in the 
management of GDM. The diagnostic criteria for GDM have been broadened thus increasing 
the patient workload to obtain the anticipated benefits indicated in the literature discussed. 
At Tygerberg Academic Hospital (TBH) pregnant women are screened for GDM using 
historical risk factors and glycosuria.   The diagnosis is not made by using a standardised oral 
glucose tolerance test, but rather by a glucose profile that comprises a fasting and 2-hour 
postprandial capillary blood glucose value after a non-standardised glycemic load (breakfast 
brought by the patient to the clinic). An audit of specific aspects of diagnosis, management 
and outcomes of the increasing population of women with GDM was deemed a valuable 
exercise to assist with future planning.  
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Chapter 3 
Research methodology  
3.1. Study setting  
Tygerberg Academic Hospital is a secondary and tertiary referral centre. Patients requiring 
secondary and tertiary care from the Metro East region of Cape Town get referrals to this 
centre for specialist management. 
3.2. Aim 
The aim of this study was to create a profile of current patients with GDM, managed 
according to the new provincial guidelines for the management of diabetes in pregnancy at 
TBH [71]. 
3.3. Objectives  
 The first objective was to determine the mode of identification of 
GDM (history, urine test, blood glucose – fasting or 2-hour value). 
 The second objective was to determine the number of patients 
requiring metformin and or insulin in addition to lifestyle modification 
(diet and exercise) for management of GDM. 
 The third objective was to determine the mode of delivery (elective or 
spontaneous) for patients with GDM. 
 The fourth objective was to determine specific perinatal outcomes for 
GDM pregnancies.   
 The fifth objective was to describe the broad profile of patients with 
GDM at TBH. 
 The sixth objective was to describe maternal complications in GDM 
pregnancies at TBH. 
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3.4. Study design 
A retrospective audit of all pregnant patients with GDM, seen at the Special Care Clinic of 
Tygerberg Academic Hospital over a period of 12 months was performed.  Patient data (see 
data capture sheet) were extracted from the files by the investigator with the assistance of 
Dr D Mason (10 of 147 files), and loaded onto a MS Excel database in a strictly anonymous 
fashion.   
3.5. Study population  
The study population comprised all pregnant women with GDM, seen at the Special Care 
Clinic of Tygerberg Academic Hospital during the period from August 2010 to July 2011. The 
dictation of the size of the study sample was by the time interval and the number of 
patients diagnosed with GDM and seen at the clinic during the period of study. 
3.6. Record review 
Files of all diabetic patients seen at the special care clinic during the study period were 
retrieved using the clinic attendance register. All retrieved files were reviewed to distinguish 
those of patients with pre-GDM from those with GDM. All files of patients with GDM were 
then reviewed to collect data as per the data collection tool. All data collected from the files 
were recorded in the data collection tool and later entered into an excel spreadsheet for 
statistical analysis.     
3.7. Statistical analysis 
STATA version 13 (StataCorp LP. 2013) was used to analyse the data [72]. Where indicated 
descriptive statistics alone were used to describe the data.  Frequencies (counts and 
percentages) and measures of location (mean and median) and spread (standard deviations, 
range and percentiles) were used depending on the distribution of the data.  95% 
confidence intervals were presented for measures of location as well as for the relative 
frequencies (proportions). 
In subsequent analyses, the patient profile as well management methods were compared to 
the delivery outcome.  Where indicated the following tests were used:  
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 Mann-Whitney test for categorical variables. 
 For categorical variables with more than two categories, the Kruskal-Wallis ANOVA. 
 Logistic regression analysis for continuous variables. 
A p-value of p < 0.05 represents statistical significance in hypothesis testing and 95% 
confidence intervals were used to describe the estimation of unknown parameters.   
3.8. Ethical considerations 
The study protocol was submitted to the University of Stellenbosch Academic Ethics 
Committee for approval (SU study number N11/01/012). After obtaining approval from the 
University’s Ethics Committee, permission to review patient records was obtained from 
Tygerberg Academic Hospital’s Research Ethics Committee via the Medical Superintendent. 
Informed consent was waivered since the study would be a retrospective audit-type record 
review. Data from patient files were extracted in a strictly anonymous fashion with no 
patient identifying data extracted. 
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Chapter 4 
Results   
Presented in this chapter are the results of the study in tables. Of the 265 records reviewed 
from the Special Care Diabetes Clinic, 147 (55.47%) records had a diagnosis of GDM and 
those 147 pregnant women with GDM accounted for 151 deliveries. 
Table 1 shows the characteristics of the study population at booking. The age of pregnant 
mothers ranged from 18 years to 46 years with an average of 32 years. The majority of 
patients were of Coloured origin (57.1%) followed by Blacks (38.1%), and only 4.8% were 
Caucasian.    
Table 1: Characteristics of the patients at booking  
Characteristic  Distribution  
Age (years)* 32 (18-46) 
Race n (%) 
Black n (%) 56 (38.1) 
Coloured n (%) 84 (57.1) 
White n (%) 7 (4.8) 
BMI (kg/m2)* 36.6 (18.4-60) 
BMI categories n (%) 
<30 n (%) 30 (20.4) 
30 – 39.9 n (%) 60 (40.8) 
≥40 n (%) 57 (38.8) 
Parity*  2 (0-6) 
*median (range), BMI = body mass index    
Table 2 outlines the statistics of the risk factor profile of the patients in the study. Those 
patients who had glycosuria in the index pregnancy were of a significant proportion (56.5%.) 
The number of glycosuria episodes in the antenatal visits at the clinic had a median of 1 and 
a range of 0-10.  
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Table 2: Risk factors of the patients at booking and after that 
Risk factor  Distribution n (%)  
Previous GDM 12 (8.2) 
Previous Big Baby ≥ 4.5kg 10 (6.8) 
Glycosuria  83 (56.5) 
Number of glycosuria episodes at ANC* 1 (0-10) 
Unexplained Previous IUD  11 (7.5) 
BMI at booking > 40kg/m2 56 (38.1) 
Maternal age > 40 years 9 (6.1) 
Family history of diabetes (primary relative) 85 (57.8) 
Family origin high prevalence of diabetes 
(Asiatic) 
1 (0.7) 
Acanthosis nigricans 2 (1.4) 
Polycystic ovarian syndrome 3 (2.0) 
*ANC = antenatal care expressed as median (range); GDM = gestational diabetes mellitus; IUD = intrauterine 
death; BMI = body mass index (calculated as weight in kilograms divided by the square of height in meters) 
Another significant proportion of patients were those with a positive family history of 
diabetes mellitus (57.8%). Importantly certain patients had a combination of risk factors for 
GDM. Table 3 shows the blood profile of patients and gestational age at diagnosis of GDM.  
Table 3:  Serum creatinine, HbA1c and gestational age at diagnosis 
Serum creatinine* 49 (20-88) 
HbA1c* 6.3 (4.8-13.5) 
Gestational age (weeks)* 28.2 (7.6-39.6) 
<24.0 weeks n (%) 41 (27.9) 
24.0-28.0 weeks n (%) 27 (18.4) 
>28.0 weeks n (%) 79 (53.7) 
*median (range) 
The patients’ files evaluation for documented episodes of hypo- and hyperglycaemia both as 
out-patients (home monitoring) or in-patients was performed. Home monitoring using a 
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glucometer was only performed on patients receiving insulin. Table 4 shows the number of 
hospital admissions as well as documented episodes of hypo- and hyperglycemia after the 
diagnosis of GDM. 
Table 4: Number of hospital admissions, hypo- and hyperglycemic episodes 
Event  Distribution  
Number of admissions post diagnosis* 1 (1-4)  
One admission# [delivery only] n (%)  81 (55.1) 
Two admissions# n (%) 44 (29.9)  
Three admissions# (%) 19 (12.9) 
Four admissions# (%)  3 (2.1) 
Episodes of hypoglycaemia*  0 (0-5) 
Episodes of hyperglycaemia*  0 (0-16) 
Home monitored$ n (%)  13 (8.8) 
*median (range) # includes delivery admission $ self- monitoring at home using a glucometer 
Of the total number of GDM patients in the study, 8.8% performed self-monitoring at home 
because of the addition of insulin to their treatment regimen.  
In the high-risk antenatal clinic at Tygerberg Academic Hospital, all patients at risk for 
intrauterine growth restriction undergo a screening measurement of the umbilical artery 
Doppler at 24 weeks of pregnancy. Pregnant patients with diabetes including GDM, T2D and 
T1D undergo an ultrasound growth scan to look for macrosomia. The growth scan involves 
measurement of the abdominal circumference (AC), mass of the baby and the amniotic fluid 
index (AFI). This examination usually includes a repeat umbilical artery Doppler 
measurement. In Table 5 the results of the screening umbilical artery Doppler measurement 
at 24 weeks’ gestation and the same examination, together with the growth scan both 
performed at 34 weeks’ gestation are given. In 59 women (39%) an ultrasound growth scan 
was not performed at 34 weeks’ gestation. 
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Table 5: Umbilical artery (UA) Doppler and key ultrasound findings 
Parameter  Distribution  
UA Doppler at 24 weeks    
Normal# n (%) 71 (47.0) 
75-95th percentile n (%) 10 (6.6) 
Not done n (%) 70 (46.4) 
Ultrasound at 34 weeks (growth scan) 
  
Mass (grams)*  2409 (1610-3315) 
Abdominal Circumference  
Normal n (%) 70 (46.4) 
>97th percentile n (%)  22 (14.6) 
Amniotic Fluid Index  
Normal n (%) 90 (59.6) 
Polyhydramnios n (%) 2 (1.3) 
UA Doppler at 34 weeks  
Normal n (%) 89 (58.9) 
75-95th percentile n (%) 6 (4.0) 
Not done n (%) 56 (37.1) 
*median (range), #resistance index < 75th percentile 
Table 6 outlines the management options used for GDM in this study. There was 
documentation of compliance with dietary and exercise advice in the patient records. Of the 
147 women in the study 34 (23%) were managed with lifestyle (diet and exercise) alone. 
One hundred (68%) required metformin in addition to lifestyle modifications and 13 (9%) 
required the additional intervention of insulin. 
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Table 6: Lifestyle and medical management of patients during pregnancy 
Intervention  Distribution  
Diet n (%) 144 (98.0) 
Exercise n (%) 93 (63.3) 
Managed by diet and exercise alone n (%) 34 (23.1) 
Metformin  
500mg BD n (%) 32 (28.3) 
500mg TDS n (%) 21 (18.6) 
850mg TDS n (%) 60 (53.1) 
Managed by lifestyle and metformin n (%) 134 (91.2) 
Insulin  
Humulin N®* n (%) 13 (8.8) 
Humulin R® (breakfast) n (%) 2 (1.4) 
Humulin R ® (lunch) n (%) 3 (2.0) 
Humulin R® (supper) n (%) 1 (0.7) 
BD = twice daily, TDS = three times daily, *all patients receiving insulin were at least on Humulin N 
Table 7 shows the details of the deliveries.  In 29.2% of cases, delivery occurred at < 38 
weeks’ gestation. Iatrogenic reasons for earlier delivery included preeclampsia in 10.9% of 
cases.  
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Table 7: Delivery details 
Outcome  Distribution  
Gestation at delivery 
<38 weeks n (%) 43 (29.2) 
≥38 <39 weeks n (%) 82 (55.8) 
>39 weeks n (%) 22 (15.0) 
Mode of delivery  
Spontaneous n (%) 40 (27.2) 
Elective n (%)  107 (72.8) 
Route of delivery  
Vaginal n (%) 66 (44.9) 
Caesarean n (%) 81 (55.1) 
Birth weight (grams)* 3280 (1230-5101) 
*median (range)  
Table 8 shows adverse outcomes of GDM affecting the mother, her baby or both. Table 9 
shows details of the two perinatal losses. 
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Table 8: Complications during pregnancy  
 Complications    Distribution n (%) 
Maternal complications  
Mothers experiencing any complication*  36 (24.5) 
Pre-eclampsia  16 (10.9) 
Late onset gestational hypertension  1 (0.7) 
Acute severe hypertension  3 (2.0) 
Preterm labour (spontaneous)  11 (7.5) 
Antepartum Haemorrhage  1 (0.7) 
Perineal Second-degree tear  1 (0.7)  
Postpartum hypertension  1 (0.7) 
Perinatal complications  
Babies experiencing any complication*  58 (38.4) 
Breech presentation  3 (2.0) 
Big baby/macrosomia  4 (2.6) 
Monochorionic diamniotic twins  1 (0.7) 
Pre-term pre-labour rupture of membranes  3 (2.0) 
Foetal distress / pathological CTG  (antenatal/intra-partum) 39 (25.8) 
Cephalo-pelvic disproportion  4 (2.6) 
Cord prolapse  1 (0.7) 
Shoulder dystocia  1 (0.7) 
Apgar scores < 7  4 (2.7) 
Neonatal hypoglycaemia  14/67 (20.9) 
Perinatal loss  2 (1.3) 
Other complications  
Any historical risk factors and labour observations*  34 (23.1) 
Previous C/S x 2  4 (2.7) 
Previous C/S x 1 declined trial of labour after C/S  4 (2.7) 
Previous C/S x 1 + breech presentation   1 (0.7) 
Previous C/S x 1 + macrosomia   1 (0.7) 
Previous C/S x 1 + failed IOL  1 (0.7) 
Previous third-degree perineal tear  1 (0.7) 
Failed induction of labour  9 (6.1) 
Poor progress during labour  13 (8.8) 
*Patients may have more than one complication. Foetal distress or pathological CTG as taken from patient 
records. CTG = cardiotocography, C/S = caesarean section, IOL = induction of labour  
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Table 9 shows the characteristics of the perinatal losses that occurred during the study 
period. One patient experienced a spontaneous miscarriage at 15 weeks’ gestation. Despite 
a positive family history and a BMI of 30 kg/m2, she had no previous diagnosis of diabetes 
mellitus, and although classified as GDM she is likely to have had pre-GDM. 
Table 9: Perinatal losses   
 Loss 1 Loss 2 
Maternal age (years) 23 29 
Gravidity and Parity  G2P1 G2P1 
Antenatal Risk factors  Glycosuria  
BMI > 40 
Family history of DM 
Uncertainty as to what risk 
factor led to diagnosis 
GA at diagnosis of GDM 30w5d 29w3d 
Management  Diet  
Exercise  
Metformin 500mg BD 
Diet  
Exercise  
Metformin 850mg TDS 
Umbilical artery  Doppler (RI)   Normal at 24 weeks  Normal at 24 weeks 
75-95th centile at 34 weeks  
Admissions  1 2 
GA at delivery 32w5d 37w2d 
Route of delivery C/S C/S 
Birth weight (grams)  1770 1710 
Complications  Unexplained IUFD followed 
by a failed IOL 
Unexplained IUFD twin B 
with signs of foetal distress 
in the other twin  
BMI = body mass index (kg/m2), DM = diabetes mellitus, GDM = gestational diabetes mellitus, GA = gestational 
age, BD = twice daily, TDS = three times daily, RI = resistance index, C/S = caesarean section, IUFD = 
intrauterine foetal death, IOL = induction of labour.    
Table 10 shows the proportions of patients and the types of medications they had 
prescribed on discharge.  
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Table 10: Medications prescribed for patients on discharge 
Medication type n (%) 
Metformin  44 (29.1) 
Anti-hypertensive medications 37 (25.2) 
Other medications* 92 (62.6) 
* Includes antibiotics, analgesics and iron supplements  
The following maternal characteristics (variables) underwent testing for association with a 
5-minute Apgar score < 7 using linear regression analysis (for continuous variables) and the 
Kruskal-Wallis test (for categorical variables): age, parity, race, BMI.  None of these 
characteristics showed any univariate statistical significance.  A second set of variables 
associated with pregnancy outcomes underwent testing for association with a 5-minute 
Apgar score < 7 in the same fashion. This second set comprised: elective delivery, Caesarean 
delivery, preeclampsia, shoulder dystocia and neonatal hypoglycaemia, none of which 
showed any univariate statistical significance. 
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Chapter 5 
Discussion 
During this year-long audit of patients with GDM, the following salient facts were noted. 
Fifty-eight percent of women had a positive family history of diabetes; 57% developed 
glycosuria, and 38% underwent diagnostic testing due to morbid obesity. Previous GDM and 
previous unexplained IUD were present in 8% of women. The median age of the women in 
this group was 32 years and 80% were found to be obese. The median gestational age at 
diagnosis was 28 weeks with a median glycosylated haemoglobin of 6.3%. The upper range 
of glycosylated haemoglobin (13.3%) and the lower range of gestational age at diagnosis (7 
weeks) indicate that cases of undiagnosed (pre-existing) diabetes mellitus were also present 
in this group of women with “gestational diabetes”.  Concerning glycemic control during 
pregnancy 23% responded to lifestyle modification alone, 68% required additional 
metformin and 9% insulin as a final addition to therapy. It is noteworthy that despite the 
diagnosis of GDM, 29% of women still required metformin at discharge. Twenty-nine 
percent of the group delivered before 38 weeks’ gestation with hypertensive complications 
(14%) and spontaneous pre-term labour (8%) featuring prominently. The median birth 
weight was 3280 grams. There was a high incidence of peripartum foetal distress (26%) 
reflected in the caesarean rate of 55%.  
The dangers of GDM are well established and the interventions to minimise the morbidity 
and mortality due to GDM are well known. Areas of importance in trying to achieve 
reduction of GDM morbidity and mortality are recognition of women at risk of GDM and 
understanding the burden of disease due to GDM.  After that, institute good management 
of GDM and long-term lifestyle modification for women who develop GDM and their 
offspring. 
5.1. Recognition of risk of gestational diabetes mellitus 
The risk factors for the development of GDM are generally well understood i.e. previous 
GDM, unexplained intrauterine death in a previous pregnancy, previous macrosomic baby 
(>4.5kg), family history of diabetes (first-degree relative with diabetes), family origin with a 
high prevalence of diabetes (Asiatic), a body mass index of more than 40kg/m2 at booking, 
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glycosuria, maternal age older than 40 years, acanthosis nigricans and polycystic ovarian 
syndrome [71]. Women may have one of these risk factors or a combination of them and in 
the latter case the risk of GDM becomes even higher. In this study the most frequent risk 
factors were: family history of diabetes (58%), glycosuria (57%) and BMI at booking greater 
than, 40kg/m2 (38%).  The other risk factors contributed smaller proportions to the overall 
risk profile of patients. Combinations of risk factors also existed increasing the individual risk 
of GDM for those particular patients. Although this study is unable to deduce what 
percentage of patients might be missed by selective screening it is clear that the large 
majority would be identified through single or combinations of risk factors.   
Recognising pre-existent risks for the development of GDM is not the only issue to consider, 
but identification of patients with GDM and no pre-existent risks in the index pregnancy is 
also important to prevent possible complications of the disease. In this study, this was 
performed by screening those patients with risk factors using urine testing for glycosuria at 
each antenatal visit and a glucose profile as indicated in the provincial management 
guidelines.  Patients with glycosuria (≥1+ of glucose on diagnostic strips) were tested as 
soon as feasibly possible with a glucose profile. Those patients with risk factors but no 
glycosuria were tested at 26 – 28 weeks of gestation [71]. Most patients in the study were 
diagnosed with GDM at gestational ages beyond 28 weeks (54%) while 28% were diagnosed 
before 24 weeks. Therefore, only 18% of patients were diagnosed during the traditional 
period of 24 – 28 weeks’ gestation. This incidence suggests that a large proportion of 
patients with GDM would be missed if testing were restricted to the traditional 24 – 28-
week period only. The influence of the other accepted risk factors can be clearly seen. The 
findings in this study are in keeping with the 2001 statement in the ACOG guidelines which, 
emphasize that insulin resistance increases with pregnancy progression and that testing 
later in pregnancy has a higher yield of abnormal results [11]. 
5.2. The burden of disease 
Gestational diabetes is known to have a significant burden of disease for the mother and 
baby not only during pregnancy and perinatal period but also over the long term. Certain 
pregnant women diagnosed with GDM might be suffering from undiagnosed, largely 
asymptomatic T2D. One would expect this to be a particular problem amongst women with 
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poor control over their diet.  Obese women are also at higher risk of preeclampsia with its 
complications, which has a high association with GDM [19, 21]. Women with diabetes are also 
more likely to deliver by primary caesarean section further increasing maternal morbidity [19, 
21]. The babies of these mothers may be macrosomic / LGA, have neonatal hyperinsulinism 
and hypoglycaemia at birth and may have shoulder dystocia and birth injury due to 
increased adiposity [19, 21].  Increased perinatal mortality has even been described [19, 21].  
In the index study, all women were managed as outpatients. Most of them (55%) achieved 
glycemic control without any admission other than that required for delivery. Episodes of 
hypoglycaemia were very few (median = 0), which is an expectation in patients with mild 
levels of dysglycemia (GDM) treated with lifestyle modification and metformin. The 
complication of hypoglycaemia is more associated with insulin treatment. Comparing the 
findings of this study with the HAPO study, patients in the index study had a more than two-
fold increase in the incidence of complications such as pre-eclampsia (11% vs. 5%) and total 
caesarean delivery (55% vs. 24%) [5]. In the post-partum period, there was a higher incidence 
of neonatal hypoglycaemia in the index study compared to the HAPO study (21% vs. 2%). 
Unfortunately, a large proportion of babies (56%) did not have glucose testing at birth 
although this was probably performed in the neonatal wards. The rate of preterm delivery 
was more than four times higher (29.2% vs. 6.9%) and that of shoulder dystocia was half of 
that reported in the HAPO study (0.7% vs. 1.3%) [5]. Of the four babies that had macrosomia, 
only one had a shoulder dystocia. All of these findings indicate the importance of timely 
diagnosis and proper management of GDM both during the antenatal and intrapartum 
periods. The perinatal loss in this study was comparable to losses in other studies (1% vs. 1% 
& 1%) [54]. 
Long-term complications that may contribute to the burden of disease due to GDM for the 
mother are: progression to T2D and risk of cardiovascular disease. For the baby the 
complications are development of overweight (obesity), pre-diabetes and T2D later in life [65, 
66, 67, 70]. In this study, the prevalence of obesity was very high with 80% of the patients 
classified as obese and 38% as morbidly obese. Comparing the weights of women in this 
study with those in the HAPO study, the median and mean weights of the patient 
populations differed (37 vs. 28 kg/m2) [5]. 
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5.3. Management of gestational diabetes mellitus 
Good management of GDM is key to preventing complications to both the mother and her 
baby. Management of GDM involves primary prevention as well as secondary prevention. 
Primary prevention entails prevention of GDM by paying attention to all the modifiable 
factors in the pre-conception period, during the pregnancy and in the post-partum period. 
Women with risk factors need pre-conception assessment for counselling and lifestyle 
modification measures (advice on weight loss, diet and exercise).  Pre-conception glycemic 
control is of relevance for patients who have previously experienced GDM. During the 
pregnancy, lifestyle modification continues to be an essential part of GDM management. 
During the post-partum period there are long term benefits to lifestyle modification such as 
maintenance of weight loss and reduction in risk of development of T2D as well as possible 
reduction in recurrence of GDM in subsequent pregnancies [19]. 
Secondary prevention entails early detection of those patients with GDM (screening and 
diagnosis) and providing treatment (lifestyle modification, oral hypoglycemic agents, insulin 
or a combination of these as necessary). Once GDM is diagnosed, patients are followed up 
more regularly to reduce or at least to detect complications early to minimise their impact.   
The patients in this study were managed using principles of secondary prevention since 
most of them got referral to the Special Care Diabetic Clinic from lower levels of care. 
Lifestyle modification forms the basis of patient management in GDM. As expected during 
pregnancy most patients, (98%) with the diet although fewer (63%) did so with exercise. 
Nearly one quarter (23%) of the patients in the index study managed to achieve 
euglycaemia using lifestyle modification (diet & exercise). Most patients (77%) required 
metformin in addition to lifestyle modification as part of their treatment for GDM and 13 
(9%) of patients required the addition of insulin to their treatment. In the well-known “MiG” 
trial the incidence of women with GDM who required the addition of insulin (to metformin) 
in order to achieve euglycaemia was much higher than the incidence of additional insulin in 
this study (46% vs.9%) [9].  
Almost one-third of patients in the index study were discharged on diabetic medications 
because their glucose levels were not controlling adequately at the time of discharge. 
However, none of the patients was discharged on insulin; only metformin was prescribed. 
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The use of Metformin is safe during lactation [71]. One-quarter of patients on discharge were 
on anti-hypertensive medications for blood pressure control post-delivery and almost two-
thirds of patients got other medications on discharge, including antibiotics, analgesics and 
iron supplements post-delivery.  
5.4. Strengths of the study 
The study sheds light on the specific patient profile, the diagnosis and management, 
perinatal outcomes and maternal complications due to GDM at Tygerberg Academic 
Hospital. It has highlighted the results of the management approach and identified gaps in 
the management of patients; e.g. limited use of growth scans at 34 weeks gestation to 
detect foetal macrosomia and insufficient measurement of serum glucose of babies to 
detect neonatal hypoglycaemia. Addressing these gaps will help to improve the quality of 
care provided. 
The retrospective audit fashion of the method of this study helped in assessing the quality 
of record keeping for patients managed at the Special Care Diabetic Clinic at TBH. 
It further contributes to the extant knowledge base that is already extensive but extending 
its borders as milder levels of dysglycemia are regarded as abnormal during pregnancy.  
Information from the study can be of potential use in redefining lines of referral from lower 
levels of health care to TBH, which is a tertiary Academic Hospital. The danger exists that 
with the expansion of the diagnostic criteria, referral hospitals can be inundated by patient 
numbers thereby hampering the provision of quality care. Decanting patients with GDM 
requiring management with lifestyle modification or low doses of metformin would help in 
ensuring that patients requiring more intensive treatment get adequate management at an 
appropriate level of care. 
 
 
 
5.5. Limitations of the study 
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The referral-based nature of the study population was a limitation to its representativity. 
This imitation would of necessity include selection bias towards sicker patients. A 
population-based study would remove such a bias.   
Incomplete records were a source of concern. Missing data does not always mean that e.g. a 
post-natal serum glucose test was not performed on a baby, it may have been done and 
found to be normal but was simply not recorded.   
The size of the study population could have been enlarged by including data from other 
years. 
5.6. Suggestions for further research 
This study could be expanded to include all levels of healthcare in the Cape Town Metro 
East region to assess the prevalence of GDM in the general population of this region. 
A comparison between different health care centres from the same region or the two Cape 
Town Metro regions could be done to assess GDM.  
5.7. Conclusion 
The presence of a positive family history, obesity and glycosuria during pregnancy are key 
elements facilitating the diagnosis of GDM, which most often occurs at the start of the third 
trimester of pregnancy. Although it is encouraging to note that one-quarter of women with 
GDM respond to lifestyle modification alone, the recent addition of the oral agent 
metformin enables the managing clinician to reserve more invasive insulin therapy to < 10% 
of cases. The goal of elective delivery at 38 weeks’ gestation is often hampered by 
complications requiring earlier delivery such as pre-eclampsia. These complications add to 
the already high caesarean rate that was 55% in the index study. It is important to separate 
undiagnosed type 2 diabetes mellitus from true gestational diabetes mellitus as the dangers 
and outcomes differ. Although an increase in the number of patients with true GDM is to be 
expected, good maternal and perinatal outcomes can be anticipated when women receive 
proper management.  
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